[go: up one dir, main page]

CA2369448A1 - Medicament for inhibiting nf-kb - Google Patents

Medicament for inhibiting nf-kb Download PDF

Info

Publication number
CA2369448A1
CA2369448A1 CA002369448A CA2369448A CA2369448A1 CA 2369448 A1 CA2369448 A1 CA 2369448A1 CA 002369448 A CA002369448 A CA 002369448A CA 2369448 A CA2369448 A CA 2369448A CA 2369448 A1 CA2369448 A1 CA 2369448A1
Authority
CA
Canada
Prior art keywords
formula
pharmaceutically acceptable
inhibiting
compounds
cox
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002369448A
Other languages
French (fr)
Other versions
CA2369448C (en
Inventor
Matthias Hamburger
Henning Danz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Zeller Soehne AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP99810750A external-priority patent/EP1078634A1/en
Application filed by Individual filed Critical Individual
Publication of CA2369448A1 publication Critical patent/CA2369448A1/en
Application granted granted Critical
Publication of CA2369448C publication Critical patent/CA2369448C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compounds of formula (I) (see formula I) wherein R1 through R8 are selected independently from hydrogen atoms and pharmaceutically acceptable substituents, as well as pharmaceutically acceptable salts of compounds of formula (I) and mixtures of substances containing at least one compound of formula (I) or a pharmaceutically acceptable salt thereof are used for preparation of medicaments for inhibiting transcription factor NF-.kappa.B and/or for inhibiting COX with a preferential inhibitory effect for COX-2.
CA002369448A 1999-04-14 2000-04-12 Medicament for inhibiting nf-kb Expired - Fee Related CA2369448C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP99810308 1999-04-14
EP99810308.9 1999-04-14
CH151999 1999-08-19
CH1519/99 1999-08-19
EP99810750.2 1999-08-20
EP99810750A EP1078634A1 (en) 1999-08-20 1999-08-20 Medicament for inhibiting NF-kB
PCT/CH2000/000214 WO2000061159A1 (en) 1999-04-14 2000-04-12 MEDICAMENT FOR INHIBITING NF-λB

Publications (2)

Publication Number Publication Date
CA2369448A1 true CA2369448A1 (en) 2000-10-19
CA2369448C CA2369448C (en) 2008-08-19

Family

ID=27173039

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002369448A Expired - Fee Related CA2369448C (en) 1999-04-14 2000-04-12 Medicament for inhibiting nf-kb

Country Status (6)

Country Link
EP (1) EP1171141B1 (en)
AT (1) ATE279933T1 (en)
AU (1) AU3548900A (en)
CA (1) CA2369448C (en)
DE (1) DE50008328D1 (en)
WO (1) WO2000061159A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102579452A (en) * 2012-01-20 2012-07-18 辽宁思百得医药科技有限公司 Preparation method of tryptanthrin compound and new application of tryptanthrin compound in preparing indoleamine-2,3-dioxygenase (IDO) inhibitor
CN103054870A (en) * 2013-01-08 2013-04-24 复旦大学 Use of tryptanthrin compound as indoleamine 2,3-dioxygenase (IDO) inhibitor
CN103570726A (en) * 2013-07-15 2014-02-12 上海天慈生物谷生物工程有限公司 N-alkyl tryptanthrin derivative, as well as preparation method and application thereof
WO2014118040A1 (en) * 2013-01-29 2014-08-07 Axel Brattstroem Extract from indigo tinctoria for the topical treatment and prophylaxis of skin disorders
CN107260743A (en) * 2016-04-05 2017-10-20 北京大学 Use of azatryptanthin derivatives as IDO1 and/or TDO inhibitors
US10059712B2 (en) 2013-11-12 2018-08-28 Fudan University N-benzyl tryptanthrin derivative, and preparation method and application thereof
CN110437233A (en) * 2019-06-21 2019-11-12 同济大学 A kind of tryptamines ketone derivatives and its preparation method and application containing olefin(e) acid
WO2022053964A1 (en) * 2020-09-11 2022-03-17 Universidade De Coimbra Water-soluble trypthantrin derivatives for redox flow batteries

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1321169A1 (en) * 2001-12-18 2003-06-25 Biofrontera Pharmaceuticals AG Combination of a serotonin receptor antagonist with a histidine decarboxylase inhibitor as a medicament
DE10315654A1 (en) * 2003-04-04 2004-11-04 Universitätsklinikum Charité an der Humboldt-Universität zu Berlin Technologietransferstelle 8-nitro-tryptanthrin and other tryptanthrin derivatives for the treatment of diseases caused by highly proliferating cells
US7256198B2 (en) 2004-02-18 2007-08-14 Wyeth Pyrimidoindolones and methods for using same
EP2709628A4 (en) * 2011-05-17 2015-04-29 Discoverybiomed Inc TREATMENT OF PROTEIN FOLDING DISORDERS WITH SMALL MOLECULE CFTR CORRECTS
CN102532144B (en) * 2012-01-20 2014-09-10 辽宁思百得医药科技有限公司 Novel indoleamine-2,3-dioxygenase inhibitor as well as preparation method and application thereof
EP2922853A4 (en) 2012-11-20 2016-11-23 Discoverybiomed Inc Small Molecule Bicyclic and Tricyclic CFTR Correctors
EP2922852A4 (en) 2012-11-20 2016-05-25 Discoverybiomed Inc CFTR SMALL MOLECULE CORRECTIVES
MX378168B (en) 2015-04-09 2025-03-10 Galderma Sa AN EXTRACT OF INDIGO NATURALIS AND A PROCESS FOR PREPARING THE SAME.
EP3209314B1 (en) 2015-04-09 2021-11-10 Galderma S.A. A pharmaceutical composition and the use thereof
JP2018510891A (en) 2015-04-09 2018-04-19 ガルデルマ・ソシエテ・アノニム Antibacterial indigo naturalis or indigo-producing plant extract and use thereof
CN105330666B (en) * 2015-11-27 2018-10-30 西北大学 Tryptamines ketone derivatives, synthetic method and its pharmaceutical usage
CN117659024A (en) * 2023-11-01 2024-03-08 安徽医科大学 An amide-substituted tryptamine derivative and its preparation method and application

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5178865A (en) * 1990-06-19 1993-01-12 Cedars-Sinai Medical Center Chinese herbal extracts in the treatment of hiv related disease in vitro
US5441955A (en) * 1993-11-19 1995-08-15 Pathogenesis Corporation Indolo[2,1-biquinazoline-6,12-dione antibacterial compounds and methods of use thereof
US5837257A (en) * 1996-07-09 1998-11-17 Sage R&D Use of plant extracts for treatment of HIV, HCV and HBV infections
US5665393A (en) * 1996-09-03 1997-09-09 International Medical Research, Inc. Herbal composition for treating prostate carcinoma
US6524625B2 (en) * 1998-06-30 2003-02-25 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyuto Physiologically active extract obtained from indigo plant polygonum tinctorium

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102579452A (en) * 2012-01-20 2012-07-18 辽宁思百得医药科技有限公司 Preparation method of tryptanthrin compound and new application of tryptanthrin compound in preparing indoleamine-2,3-dioxygenase (IDO) inhibitor
CN103054870A (en) * 2013-01-08 2013-04-24 复旦大学 Use of tryptanthrin compound as indoleamine 2,3-dioxygenase (IDO) inhibitor
WO2014118040A1 (en) * 2013-01-29 2014-08-07 Axel Brattstroem Extract from indigo tinctoria for the topical treatment and prophylaxis of skin disorders
US9630969B2 (en) 2013-07-15 2017-04-25 Shanghai Tin Tsz Bio Valley Biological Engineering Co., Ltd N-alkyl tryptanthrin derivative, preparation method for same, and application thereof
WO2015007249A1 (en) * 2013-07-15 2015-01-22 上海天慈生物谷生物工程有限公司 N-alkyl tryptanthrin derivative, preparation method for same, and application thereof
CN103570726B (en) * 2013-07-15 2016-04-06 上海天慈生物谷生物工程有限公司 N-alkyl couroupitine A derivative and its preparation method and application
CN103570726A (en) * 2013-07-15 2014-02-12 上海天慈生物谷生物工程有限公司 N-alkyl tryptanthrin derivative, as well as preparation method and application thereof
US10059712B2 (en) 2013-11-12 2018-08-28 Fudan University N-benzyl tryptanthrin derivative, and preparation method and application thereof
CN107260743A (en) * 2016-04-05 2017-10-20 北京大学 Use of azatryptanthin derivatives as IDO1 and/or TDO inhibitors
CN107260743B (en) * 2016-04-05 2020-01-31 北京大学 Use of Azatryptamine Derivatives as IDO1 and/or TDO Inhibitors
US10669273B2 (en) 2016-04-05 2020-06-02 Peking University Use of aza-tryptanthrin derivatives as inhibitors of IDO1 and/or TDO
CN110437233A (en) * 2019-06-21 2019-11-12 同济大学 A kind of tryptamines ketone derivatives and its preparation method and application containing olefin(e) acid
CN110437233B (en) * 2019-06-21 2022-01-07 同济大学 Tryptanthrin derivative containing olefine acid and preparation method and application thereof
WO2022053964A1 (en) * 2020-09-11 2022-03-17 Universidade De Coimbra Water-soluble trypthantrin derivatives for redox flow batteries

Also Published As

Publication number Publication date
EP1171141B1 (en) 2004-10-20
AU3548900A (en) 2000-11-14
CA2369448C (en) 2008-08-19
DE50008328D1 (en) 2004-11-25
ATE279933T1 (en) 2004-11-15
WO2000061159A1 (en) 2000-10-19
EP1171141A1 (en) 2002-01-16

Similar Documents

Publication Publication Date Title
CA2369448A1 (en) Medicament for inhibiting nf-kb
WO2004055005A8 (en) Novel compounds having selective inhibiting effect at gsk3
MXPA04004674A (en) Cannabinoid receptor ligands.
SI0937041T1 (en) Use of a pharmaceutically acceptable salt of (3R,2'R)-3-((Cyclopently-hydroxyphenylacetyl)oxy)-1,1-dimethyl-pyrrolidinium for the preparation of a medicament
WO2004085385A3 (en) Cannabinoid receptor ligands
HUP0204405A2 (en) Water soluble prodrugs of azole compounds
DK0928788T3 (en) Imidazolidin-4-one derivatives useful as anticancer agents
CA2358998A1 (en) Substituted bicyclic derivatives useful as anticancer agents
NZ512883A (en) 2-oxoquinoline compounds and medicinal uses thereof
WO2004112710A3 (en) COMPOSITIONS AND METHODS FOR INHIBITING TGF-ß
CA2341690A1 (en) Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents
ATE218345T1 (en) DRUGS FOR SPINOCEREBELLAR DEGENERATION
CA2373117A1 (en) 13-methyl-erythromycin derivatives
HK1042303A1 (en) New compounds
EP0765865A4 (en) 2-acylaminopropanol compound and medicinal composition
WO2002016312A3 (en) NOVEL COMPOUNDS INHIBITING FACTOR Xa ACTIVITY
EP1277744A4 (en) Oxadiazole derivatives having anticancer effects
WO2001081316A3 (en) Substituted phenyl farnesyltransferase inhibitors
WO2001027110A3 (en) Bicyclic imidazo-3-yl-amine derivatives which are substituted on the sixth ring
ZA200203305B (en) Benzothiadiazine derivatives, preparation method and pharmaceutical compositions containing same.
EP1142881A4 (en) Poly(adp-ribose) polymerase inhibitors consisting of pyrimidine derivatives
CA2179015A1 (en) Use of bis(amidinobenzimidazoles) in the manufacture of medicament for inhibiting retroviral integrase
CA2365359A1 (en) Medicaments containing a sulfopyranosylglycerol derivative
WO2000066550A8 (en) New compounds
WO2005053702A3 (en) Anti-inflammatory agents

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150413